Ulteriori informazioni
Based on the most novel approaches and cutting-edge clinical and scientific information regarding radionuclide imaging and therapies for neuroendocrine tumors, this clinical guidebook represents a unique collaborative effort between endocrinologists, nuclear physicians, oncologists, surgeons, physicists, radio-pharmacists and geneticists. It begins with the embryology, classification and molecular genetics of gastroenteropancreatic neuroendocrine tumors and carcinoids, chromaffin cell tumors, and MEN1- and MEN2-related tumors. Following a chapter on radiopharmaceuticals in neuroendocrine imaging, it turns to the physics and technology of current and cutting-edge radiology, including SPECT/CT and PET/CT and PET/MR. Discussing of radionuclide imaging covers the tumors mentioned above, as well as pulmonary and thymic neuroendocrine tumors and medullary thyroid carcinoma. A presentation of radionuclide therapies follows, including 131I-MIBG therapy, somatostatin receptor-based therapy, andalpha radionuclide therapy, as well as the role of nanoparticles.
Comprehensive and up-to-date, Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors will assist and guide physicians who encounter patients with these conditions, either from a diagnostic or therapeutic standpoint, and particularly emphasizes the current and emerging medical devices and imaging and therapeutic options.
Sommario
Classification of neuroendocrine tumors.- Molecular genetics of Pheochromocytoma and paraganglioma.- Molecular Genetics of MEN1-related Neuroendocrine Tumors.- Molecular genetics of MEN2-related neuroendocrine tumors.- Molecular genetics of Neuroblastoma.- Molecular Genetics of Gastroenteropancreatic Neuroendocrine Tumors.- Current and future radiopharmaceuticals in neuroendocrine tumors imaging.- SPECT/CT, PET/CT and PET/MR: Principles.- Internal dosimetry: Principles and Applications to NET.- Principles and Application of Molecular Imaging for Personalised Medicine and Guiding Interventions in Neuroendocrine Tumors.- Tumor metabolism and metabolomics of pheochromocytomas and paragangliomas.- Radionuclide imaging of pheochromocytoma and paraganglioma in the era of multi-omics.- Radionuclide imaging of Head and neck PGLs.- Radionuclide imaging of Chromaffin cell tumors.- Radionuclide imaging of Gastrointestinal neuroendocrine tumors.- Radionuclide imaging of Pancreatic neuroendocrine tumors.- Radionuclide imaging of Pulmonary, thymic neuroendocrine tumors and other neuroendocrine tumors.- Radionuclide imaging of Medullary thyroid carcinoma.- 131I-MIBG therapy for pheochromocytoma/paraganglioma and neuroblastoma.- Somatostatin receptors-based radionuclide therapy.- Alpha radionuclide therapy: Principles and Applications to NET.- Nanoparticles for Radionuclide Imaging and Therapy: Principles.
Info autore
Karel Pacak, MD, PhD, DSc, Senior Investigator and Chief, Section on Medical Neuroendocrinology, Professor of Medicine, Eunice Kennedy Shriver NICHD/NIH, Bethesda, MD, USA
David Taieb, MD, PhD, Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France
Riassunto
Based on the most novel approaches and cutting-edge clinical and scientific information regarding radionuclide imaging and therapies for neuroendocrine tumors, this clinical guidebook represents a unique collaborative effort between endocrinologists, nuclear physicians, oncologists, surgeons, physicists, radio-pharmacists and geneticists. It begins with the embryology, classification and molecular genetics of gastroenteropancreatic neuroendocrine tumors and carcinoids, chromaffin cell tumors, and MEN1- and MEN2-related tumors. Following a chapter on radiopharmaceuticals in neuroendocrine imaging, it turns to the physics and technology of current and cutting-edge radiology, including SPECT/CT and PET/CT and PET/MR. Discussing of radionuclide imaging covers the tumors mentioned above, as well as pulmonary and thymic neuroendocrine tumors and medullary thyroid carcinoma. A presentation of radionuclide therapies follows, including 131I-MIBG therapy, somatostatin receptor-based therapy, andalpha radionuclide therapy, as well as the role of nanoparticles.
Comprehensive and up-to-date, Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors will assist and guide physicians who encounter patients with these conditions, either from a diagnostic or therapeutic standpoint, and particularly emphasizes the current and emerging medical devices and imaging and therapeutic options.
